CatalystFDA/Bio

FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug

FDA priority review accelerates AZN's rare bone disease drug filing.

What changed

FDA priority review accelerates AZN's rare bone disease drug filing.

Why it matters

FDA priority review accelerates AZN's rare bone disease drug filing. — impact context not separately stored; see What changed.

Sources